MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Infliximab

Selected References:

  • Babuna Kobaner G, Polat Ekinci A. 2020. Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: Report of a challenging case. Dermatologic Therapy. 33(4): e13571
  • Bröms G, et al. 2020. Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf. 29(3):316-327.
  • Beaulieu DB, et al. 2018. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol. 16:99-105.Carter JD, et al. 2009. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol. 36(3):635-41.
  • Carter JD, et al. 2006. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. J Rheumatol33(5):1014-1017.
  • Chaparro M, Gisbet JP. 2014. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease. Expert Opin Drug Saf. 13(12):1749-62.
  • Dernoncourt A, et al. 2023. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: insights from an analysis of the World Health Organization Pharmacovigilance Database (VigiBase®). BioDrugs. 37(1):73-87.
  • Geldhof A, et al. 2020. Exposure to infliximab during pregnancy: Post-marketing experience. Drug Saf. 43(2):147-161.
  • Goulden B, et al. 2022. A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero. Rheumatology (Oxford). 6;61(10):3902-3906.
  • Grgić, D., et al. 2020. Pregnancy-onset acute severe colitis after in vitro fertilization embryo transfer. Case reports in gastroenterology. 14(3):477–482.
  • Heller MM, et al. 2011. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. J Am Acad Dermatol. 65(4):870.
  • Kanis SL, et al. 2021. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. Gut. 70(7):1266-1274..
  • Mahadevan U, et al. 2013. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 11(3):286-92.
  • Mahadevan U, et al. 2021. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology. 160(4):1131-1139.
  • Meserve J, et al. 2021. Paternal exposure to immunosuppressive and/or biologic agents and birth outcomes in patients with immune-mediated inflammatory diseases. Gastroenterology. 161(1):107-115.e3.
  • Micu MC, et al. 2014. TNF-α inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment. Rheumatology (Oxford). 53(7):1250-5.
  • Mouyis M, et al. 2019. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. Semin Arthritis Rheum. 48(5):911-920.
  • Saougou I, et al. 2013. Fertility in male patients with seronegative spondyloarthropathies treated with infliximab. Joint Bone Spine. 80(1):34-37.
  • Snoeckx Y, et al. 2008. Pregnancy outcomes in women taking infliximab: The infliximab safety database. Arthr Rheum. 58:S426.
  • Weber-Schoendorfer C, et al. 2015. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. British Journal of Clinical Pharmacology. 80(4):727-739.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.